|
1
|
Yaxley JP: Urinary tract cancers: An
overview for general practice. J Family Med Prim Care. 5:533–538.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lenis AT, Lec PM, Chamie K and Mshs MD:
Bladder cancer: A review. JAMA. 324:1980–1991. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Griffiths TR; Action on Bladder Cancer, :
Current perspectives in bladder cancer management. Int J Clin
Pract. 67:435–448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ritch CR, Velasquez MC, Kwon D, Becerra
MF, Soodana-Prakash N, Atluri VS, Almengo K, Alameddine M, Kineish
O, Kava BR, et al: Use and validation of the AUA/SUO risk grouping
for nonmuscle invasive bladder cancer in a contemporary cohort. J
Urol. 203:505–511. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yafi FA, Aprikian AG, Chin JL, Fradet Y,
Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, et
al: Contemporary outcomes of 2287 patients with bladder cancer who
were treated with radical cystectomy: A Canadian multicentre
experience. BJU Int. 108:539–545. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perera M, McGrath S, Sengupta S, Crozier
J, Bolton D and Lawrentschuk N: Pelvic lymph node dissection during
radical cystectomy for muscle-invasive bladder cancer. Nat Rev
Urol. 15:686–692. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patel VG, Oh WK and Galsky MD: Treatment
of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J
Clin. 70:404–423. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chamie K, Litwin MS, Bassett JC, Daskivich
TJ, Lai J, Hanley JM, Konety BR and Saigal CS; Urologic Diseases in
America Project, : Recurrence of high-risk bladder cancer: A
population-based analysis. Cancer. 119:3219–3227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sabharwal SS and Schumacker PT:
Mitochondrial ROS in cancer: Initiators, amplifiers or an Achilles'
heel? Nat Rev Cancer. 14:709–721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pizzino G, Irrera N, Cucinotta M, Pallio
G, Mannino F, Arcoraci V, Squadrito F, Altavilla D and Bitto A:
Oxidative stress: Harms and benefits for human health. Oxid Med
Cell Longev. 2017:84167632017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cohen Z, Maimon Y, Samuels N and Berger R:
Role of reactive oxygen species in the anticancer activity of
botanicals: Comparing sensitivity profiles. Oncol Lett.
13:2642–2648. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kumari S, Badana AK, Mohan GM, Shailender
G and Malla R: Reactive oxygen species: A key constituent in cancer
survival. Biomark Insights. 13:11772719187553912018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Trachootham D, Alexandre J and Huang P:
Targeting cancer cells by ROS-mediated mechanisms: A radical
therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moloney JN and Cotter TG: ROS signalling
in the biology of cancer. Semin Cell Dev Biol. 80:50–64. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen SY, Huang HY, Lin HP and Fang CY:
Piperlongumine induces autophagy in biliary cancer cells via
reactive oxygen species-activated Erk signaling pathway. Int J Mol
Med. 44:1687–1696. 2019.PubMed/NCBI
|
|
17
|
Lin S, Li Y, Zamyatnin AA Jr, Werner J and
Bazhin AV: Reactive oxygen species and colorectal cancer. J Cell
Physiol. 233:5119–5132. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang H, Xie H, Pan Y, Zheng K, Xia Y and
Chen W: Plumbagin triggers ER stress-mediated apoptosis in prostate
cancer cells via induction of ROS. Cell Physiol Biochem.
45:267–280. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang L, Li J, Zong L, Chen X, Chen K,
Jiang Z, Nan L, Li X, Li W, Shan T, et al: Reactive oxygen species
and targeted therapy for pancreatic cancer. Oxid Med Cell Longev.
2016:16167812016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sharma V, Joseph C, Ghosh S, Agarwal A,
Mishra MK and Sen E: Kaempferol induces apoptosis in glioblastoma
cells through oxidative stress. Mol Cancer Ther. 6:2544–2553. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zou Z, Chang H, Li H and Wang S: Induction
of reactive oxygen species: An emerging approach for cancer
therapy. Apoptosis. 22:1321–1335. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gorrini C, Harris IS and Mak TW:
Modulation of oxidative stress as an anticancer strategy. Nat Rev
Drug Discov. 12:931–947. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chaffman M, Brogden RN, Heel RC, Speight
TM and Avery GS: Auranofin. A preliminary review of its
pharmacological properties and therapeutic use in rheumatoid
arthritis. Drugs. 27:378–424. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee D, Xu IM, Chiu DK, Leibold J, Tse AP,
Bao MH, Yuen VW, Chan CY, Lai RK, Chin DW, et al: Induction of
oxidative stress through inhibition of thioredoxin reductase 1 is
an effective therapeutic approach for hepatocellular carcinoma.
Hepatology. 69:1768–1786. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wen C, Wang H, Wu X, He L, Zhou Q, Wang F,
Chen S, Huang L, Chen J, Wang H, et al: ROS-mediated inactivation
of the PI3K/AKT pathway is involved in the antigastric cancer
effects of thioredoxin reductase-1 inhibitor chaetocin. Cell Death
Dis. 10:8092019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oh BM, Lee SJ, Cho HJ, Park YS, Kim JT,
Yoon SR, Lee SC, Lim JS, Kim BY, Choe YK and Lee HG: Cystatin SN
inhibits auranofin-induced cell death by autophagic induction and
ROS regulation via glutathione reductase activity in colorectal
cancer. Cell Death Dis. 8:e30532017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimada K, Fujii T, Anai S, Fujimoto K and
Konishi N: ROS generation via NOX4 and its utility in the
cytological diagnosis of urothelial carcinoma of the urinary
bladder. BMC Urol. 11:222011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miyata Y, Matsuo T, Sagara Y, Ohba K,
Ohyama K and Sakai H: A mini-review of reactive oxygen species in
urological cancer: Correlation with NADPH oxidases, angiogenesis,
and apoptosis. Int J Mol Sci. 18:22142017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chou TC and Talaly P: A simple generalized
equation for the analysis of multiple inhibitions of
michaelis-menten kinetic systems. J Biol Chem. 252:6438–6442. 1977.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Malumbres M: Cyclin-dependent kinases.
Genome Biol. 15:1222014. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sgambato A, Cittadini A, Faraglia B and
Weinstein IB: Multiple functions of p27(Kip1) and its alterations
in tumor cells: A review. J Cell Physiol. 183:18–27. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Roskoski R Jr: Cyclin-dependent protein
serine/threonine kinase inhibitors as anticancer drugs. Pharmacol
Res. 139:471–488. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen T and Huang S: The role of Cdc25A in
the regulation of cell proliferation and apoptosis. Anticancer
Agents Med Chem. 12:631–639. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bartek J and Lukas J: Mammalian G1- and
S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol.
13:738–747. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Falck J, Petrini JH, Williams BR, Lukas J
and Bartek J: The DNA damage-dependent intra-S phase checkpoint is
regulated by parallel pathways. Nat Genet. 30:290–294. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Falck J, Mailand N, Syljuåsen RG, Bartek J
and Lukas J: The ATM-Chk2-Cdc25A checkpoint pathway guards against
radioresistant DNA synthesis. Nature. 410:842–847. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Drayton RM and Catto JW: Molecular
mechanisms of cisplatin resistance in bladder cancer. Expert Rev
Anticancer Ther. 12:271–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim SJ, Kim HS and Seo YR: Understanding
of ROS-inducing strategy in anticancer therapy. Oxid Med Cell
Longev. 2019:53816922019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kirtonia A, Gala K, Fernandes SG, Pandya
G, Pandey AK, Sethi G, Khattar E and Garg M: Repurposing of drugs:
An attractive pharmacological strategy for cancer therapeutics.
Semin Cancer Biol. 68:258–278. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hernandez JJ, Pryszlak M, Smith L, Yanchus
C, Kurji N, Shahani VM and Molinski SV: Giving drugs a second
chance: Overcoming regulatory and financial hurdles in repurposing
approved drugs as cancer therapeutics. Front Oncol. 7:2732017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Onodera T, Momose I and Kawada M:
Potential anticancer activity of auranofin. Chem Pharm Bull
(Tokyo). 67:186–191. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang X, Selvaraju K, Saei AA, D'Arcy P,
Zubarev RA, Arnér ES and Linder S: Repurposing of auranofin:
Thioredoxin reductase remains a primary target of the drug.
Biochimie. 162:46–54. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hwang-Bo H, Jeong JW, Han MH, Park C, Hong
SH, Kim GY, Moon SK, Cheong J, Kim WJ, Yoo YH and Choi YH:
Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis
in hepatocellular carcinoma Hep3B cells by generation of reactive
oxygen species. Gen Physiol Biophys. 36:117–128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cui XY, Park SH and Park WH: Auranofin
inhibits the proliferation of lung cancer cells via necrosis and
caspase-dependent apoptosis. Oncol Rep. 44:2715–2724. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Karsa M, Kosciolek A, Bongers A, Mariana
A, Failes T, Gifford AJ, Kees UR, Cheung LC, Kotecha RS, Arndt GM,
et al: Exploiting the reactive oxygen species imbalance in
high-risk paediatric acute lymphoblastic leukaemia through
auranofin. Br J Cancer. 125:55–64. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kuczler MD, Olseen AM, Pienta KJ and Amend
SR: ROS-induced cell cycle arrest as a mechanism of resistance in
polyaneuploid cancer cells (PACCs). Prog Biophys Mol Biol. 165:3–7.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Nadal R and Bellmunt J: Management of
metastatic bladder cancer. Cancer Treat Rev. 76:10–21. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Roberts JT, von der Maase H, Sengeløv L,
Conte PF, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine/cisplatin and
methotrexate/vinblastine/doxorubicin/cisplatin in patients with
locally advanced and metastatic bladder cancer. Ann Oncol. 17
(Suppl 5):v118–v122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Narayan RS, Molenaar P, Teng J,
Cornelissen FMG, Roelofs I, Menezes R, Dik R, Lagerweij T, Broersma
Y, Petersen N, et al: A cancer drug atlas enables synergistic
targeting of independent drug vulnerabilities. Nat Commun.
11:29352020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Saad SY, Najjar TA and Alashari M: Role of
non-selective adenosine receptor blockade and phosphodiesterase
inhibition in cisplatin-induced nephrogonadal toxicity in rats.
Clin Exp Pharmacol Physiol. 31:862–867. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu X, Wang W, Yin Y, Li M, Li H, Xiang H,
Xu A, Mei X, Hong B and Lin W: A high-throughput drug screen
identifies auranofin as a potential sensitizer of cisplatin in
small cell lung cancer. Invest New Drugs. 37:1166–1176. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
He W, Xia Y, Cao P, Hong L, Zhang T, Shen
X, Zheng P, Shen H, Liang G and Zou P: Curcuminoid WZ35 synergize
with cisplatin by inducing ROS production and inhibiting TrxR1
activity in gastric cancer cells. J Exp Clin Cancer Res.
38:2072019. View Article : Google Scholar : PubMed/NCBI
|
